SCHEMBL23328883

SCHEMBL23328883

Cc1ccc2nc(NC(=O)NCS(=O)(=O)O)sc2c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP1 P24666 2/20 0.70
DYRK1A Q13627 1/20 0.64
KMT2A Q03164 5/20 0.59
NPC1 O15118 10/20 0.59
RAB9A P51151 10/20 0.59
SMN1; SMN2 Q16637 7/20 0.59
TP53 P04637 3/20 0.59
PTPN1 P18031 1/20 0.58
ALDH1A1 P00352 4/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
MITF O75030 1/20 0.57
POLB P06746 1/20 0.57
APEX1 P27695 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
LMNA P02545 4/20 0.56
ABL1 P00519 1/20 0.56
CSNK1D P48730 1/20 0.55
MEN1 O00255 4/20 0.54
KDM4E B2RXH2 2/20 0.54
NFKB1 P19838 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14189671 0.86 ABL1 (0.70) ACP1DYRK1ANPC1RAB9ASMN1; SMN2
SCHEMBL2793209 0.84 DYRK1A (0.65) ACP1DYRK1AKMT2ANPC1RAB9A
SCHEMBL23328380 0.82 NPC1 (0.71) ACP1DYRK1AKMT2ANPC1RAB9A
Potassium Ion SCHEMBL2815064 0.81 DYRK1A (0.62) ACP1DYRK1AKMT2ANPC1RAB9A
SCHEMBL5019481 0.81 DYRK1A (0.74) ACP1DYRK1AKMT2ANPC1RAB9A
SCHEMBL2175580 0.78 DYRK1A (1.00) ACP1DYRK1AKMT2ANPC1RAB9A
SCHEMBL14189669 0.78 RAB9A (0.74) ACP1DYRK1AKMT2ANPC1RAB9A
SCHEMBL13486495 0.77 DYRK1A (0.76) ACP1DYRK1AKMT2ANPC1RAB9A
SCHEMBL4124786 0.77 DYRK1A (0.74) ACP1DYRK1AKMT2ANPC1RAB9A
SCHEMBL10936133 0.76 DYRK1A (0.74) ACP1DYRK1AKMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11701333-B2 Antibacterial compounds Kent Innovation & Enterprise (GB) 2023-07-18 US disclosed
US-11701333-B2 Antibacterial compounds Kent Innovation & Enterprise (GB) 2023-07-18 US disclosed
US-20210128501-A1 ANTIBACTERIAL COMPOUNDS KENT INNOVATION & ENTERPRISE, UNIVERSITY OF KENT (GB) 2021-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11701333-B2 Antibacterial compounds ARF1, ARL1, TLR1 ACP1 4001/4885DYRK1A 4733/4885KMT2A 2533/4885
US-20210128501-A1 ANTIBACTERIAL COMPOUNDS ARF1, ARL1, TLR1 ACP1 4001/4885DYRK1A 4733/4885KMT2A 2533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.